Gyre Therapeutics
A majority-owned Beijing unit sells China's pirfenidone lung-fibrosis therapy while San Diego runs the antifibrotic pipeline.
Something off on this page? Send us feedback.
Profile
A majority-owned Beijing subsidiary generates nearly all revenue selling pirfenidone-based and related therapies for lung and liver conditions across Chinese hospitals and pharmacies, while a separate San Diego unit develops hydronidone for liver fibrosis and, following a 2026 acquisition, an early-stage protein-degradation drug platform. A Japanese parent holds voting control.
A majority-owned Beijing subsidiary sells an established pirfenidone therapy for idiopathic pulmonary fibrosis through Chinese hospitals and pharmacies, joined in 2025 by a nintedanib antifibrotic and a drug for liver-disease-related low platelet counts. This subsidiary generates nearly all revenue, funding a separate San Diego development unit.
That unit is advancing hydronidone, a pirfenidone derivative, toward conditional approval in China for hepatitis-B-related liver fibrosis, with a US study in fatty-liver fibrosis planned next. A 2026 stock acquisition of Cullgen added a protein-degradation drug-discovery platform and early-stage oncology candidates.
Voting control rests with a Japanese parent holding a large majority of common shares, a structure dating to the 2023 reverse merger that combined a dormant Nasdaq shell with the Beijing drugmaker under the current name. Two reportable segments track this same China-commercial, US-development split.
Company facts
Key statistics
Year to date −3.1% · Average volume (30d) 52.1K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026Q2 FY26 | −$0.06 | −$0.12 | −111.8% | $26.5M | $29.1M | +9.9% | +4.22% |
| May 7, 2026Q1 FY26 | −$0.06 | −$0.05 | +16.7% | $31.6M | $22.5M | −28.8% | +5.66% |
| Mar 12, 2026Q4 FY25 | $0.06 | $0.04 | −29.4% | $35.4M | $37.2M | +5.0% | −3.20% |
| Nov 7, 2025Q3 FY25 | $0.05 | $0.06 | +20.0% | $36.3M | $30.6M | −15.8% | +9.85% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $22.1M | $29.7M | $30.6M | $37.2M | $22.5M | $29.1M | |
| Gross profit | $21.2M | $25.6M | $28.9M | $35.5M | $21.3M | $26.9M | |
| Operating income | $2.3M | $2.2M | $6.9M | $120.0K | −$9.4M | −$14.4M | |
| Net income | $2.7M | $598.0K | $3.6M | −$1.7M | −$8.6M | −$10.6M | |
| Diluted EPS | $0.00 | −$0.03 | $0.03 | −$0.02 | −$0.10 | −$0.12 | |
| Gross margin | 95.9% | 86.2% | 94.7% | 95.3% | 94.6% | 92.4% | |
| Operating margin | 10.3% | 7.3% | 22.7% | 0.3% | -41.5% | -49.3% |
Fiscal years (4-quarter sums)FY21 $7.3M · FY22 $58.4M · FY23 $113.5M · FY24 $105.8M · FY25 $119.6M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $74.8M · Total debt $3.4M · Total assets $199.3M · Shareholders' equity $130.4M
Dividends
Last cut to $0.24 from $1.43 in Jan 2023.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jan 13, 2023 | Jan 5 | $0.24 | cut from $1.43 | |
| Sep 21, 2022 | Sep 6 | $1.43 |
Ownership
Shares outstanding 111.49M · Float 32.86M · 29.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| GNI USA, Inc. | 86.32M | 69.10% | 13D | May 6, 2026 |
| Ping Lan | 10.21M | 8.60% | 13D | May 6, 2026 |
| Songjiang Ma | 7.34M | 6.33% | 13D | May 7, 2026 |
| SC China Holding Ltd | 3.75M | 3.36% | 13F | Aug 13, 2026 |
| Ying Luo · director, officer: Chief Executive Officer | 2.57M | 2.30% | Form 4 | May 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 18, 2026 | Weiguo Ye | officer: Chief Operating Officer | −3,000 | $6.35 |
| Jun 10, 2026 | Weiguo Ye | officer: Chief Operating Officer | −11,418 | $6.22 |
| Jun 9, 2026 | Weiguo Ye | officer: Chief Operating Officer | −17,500 | $6.14 |
| Jun 11, 2026 | Weiguo Ye | officer: Chief Operating Officer | −2,800 | $6.17 |
| Jun 4, 2026 | Weiguo Ye | officer: Chief Operating Officer | −19,575 | $6.13 |
Peers
- Madrigal Pharmaceuticals
First FDA-approved MASH treatment on market since 2024, the entrenched leader
- Novo Nordisk (ADR)
Acquired Akero's EFX/SYNCHRONY (FGF21) MASH asset; semaglutide approved for MASH
- Arvinas
Clinical-stage PROTAC pioneer with an FDA-approved degrader, same TPD modality
- Kymera Therapeutics
Clinical-stage oral degrader developer with a more advanced immunology pipeline
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Gyre Therapeutics | $6.59 | −0.15% | $734.7M | — | — | 6.2 | +8.7% |
| Madrigal Pharmaceuticals | $533.76 | −0.02% | $12.33B | — | — | 9.6 | +71.2% |
| Novo Nordisk (ADR) | $45.60 | +0.00% | $202.54B | 11.2 | 18.4 | 4.0 | +0.0% |
| Arvinas | $9.18 | +0.05% | $592.3M | 57.4 | — | 1.9 | +1,014.7% |
| Kymera Therapeutics | $118.15 | +0.06% | $9.72B | — | — | 92.6 | +466.4% |
| Median | 34.3 | 18.4 | 6.8 | +268.8% |